CPP-assisted intracellular drug delivery, what is next?

International Journal of Molecular Sciences

Volumn 17, Issue 11, 2016, Pages

  Ye, Junxiao ^a,b   Liu, Ergang ^a,b   Yu, Zhili ^b   Pei, Xing ^b   Chen, Sunhui ^b   Zhang, Pengwei ^a,b   Shin, Meong Cheol ^c   Gong, Junbo ^a   He, Huining ^b   Yang, Victor C ^b,d  

^a TIANJIN UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c Gyeongsang National University   (South Korea)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

CPPs; Intracellular delivery; PH and enzyme triggered drug delivery system

Indexed keywords

ASPARAGINASE; CELL PENETRATING PEPTIDE; DOXORUBICIN; HYDRAZONE DERIVATIVE; MATRIX METALLOPROTEINASE; POLYETHYLENEIMINE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; ANTINEOPLASTIC AGENT; DRUG CARRIER;

BLOOD BRAIN BARRIER; DRUG DELIVERY SYSTEM; ENCAPSULATION; ENDOCYTOSIS; ENZYMATIC DEGRADATION; HUMAN; HYDROLYSIS; INTERNALIZATION; INTRACELLULAR TRANSPORT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PH; PINOCYTOSIS; REVIEW; SEQUENCE ANALYSIS; STATIC ELECTRICITY; TUMOR MICROENVIRONMENT; ANIMAL; NEOPLASMS; PERMEABILITY; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL-PENETRATING PEPTIDES; DRUG CARRIERS; ENDOCYTOSIS; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS; PERMEABILITY; TISSUE DISTRIBUTION;

EID: 84995701398     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17111892     Document Type: Review

References (114)

1. Koren, E.; Torchilin, V.P. Cell-penetrating peptides: Breaking through to the other side. Trends Mol. Med. 2012, 18, 385–393.
2. Fawell, S.; Seery, J.; Daikh, Y.; Moore, C.; Chen, L.L.; Pepinsky, B.; Barsoum, J. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. USA 1994, 91, 664–668.
3. Torchilin, V. Intracellular delivery of protein and peptide therapeutics. Drug Discov. Today Technol. 2008, 5, e95–e103.
4. Allen, T.M.; Cullis, P.R. Drug delivery systems: Entering the mainstream. Science 2004, 303, 1818–1822.
5. Morris, M.C.; Deshayes, S.; Heitz, F.; Divita, G. Cell-penetrating peptides: From molecular mechanisms to therapeutics. Biol. Cell 2008, 100, 201–217.
6. Torchilin, V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006, 8, 343–375.
7. Conner, S.D.; Schmid, S.L. Regulated portals of entry into the cell. Nature 2003, 422, 37–44.
8. El-Sayed, A.; Futaki, S.; Harashima, H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: Ways to overcome endosomal entrapment. AAPS J. 2009, 11, 13–22.
9. Varkouhi, A.K.; Scholte, M.; Storm, G.; Haisma, H.J. Endosomal escape pathways for delivery of biologicals. J. Control. Release 2011, 151, 220–228.
10. Gupta, B.; Levchenko, T.S.; Torchilin, V.P. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv. Drug Deliv. Rev. 2005, 57, 637–651.
11. Brooks, H.; Lebleu, B.; Vives, E. Tat peptide-mediated cellular delivery: Back to basics. Adv. Drug Deliv. Rev. 2005, 57, 559–577.
12. Brasseur, R.; Divita, G. Happy birthday cell penetrating peptides: Already 20 years. Biochim. Biophys. Acta 2010, 1798, 2177–2181.
13. Hallbrink, M.; Floren, A.; Elmquist, A.; Pooga, M.; Bartfai, T.; Langel, U. Cargo delivery kinetics of cell-penetrating peptides. Biochim. Biophys. Acta 2001, 1515, 101–109.
14. Heitz, F.; Morris, M.C.; Divita, G. Twenty years of cell-penetrating peptides: From molecular mechanisms to therapeutics. Br. J. Pharmacol. 2009, 157, 195–206.
15. Deshayes, S.; Morris, M.C.; Divita, G.; Heitz, F. Cell-penetrating peptides: Tools for intracellular delivery of therapeutics. Cell. Mol. Life Sci. 2005, 62, 1839–1849.
16. Dietz, G.P.; Kilic, E.; Bahr, M. Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol. Cell. Neurosci. 2002, 21, 29–37.
17. Kwon, Y.M.; Li, Y.T.; Liang, J.F.; Park, Y.J.; Chang, L.C.; Yang, V.C. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: A proof-of-concept investigation. J. Control. Release 2008, 130, 252–258.
18. Zhao, M.; Weissleder, R. Intracellular cargo delivery using tat peptide and derivatives. Med. Res. Rev. 2004, 24, 1–12.
19. Vives, E. Present and future of cell-penetrating peptide mediated delivery systems: Is the Trojan horse too wild to go only to Troy? J. Control. Release 2005, 109, 77–85.
20. Vives, E.; Brodin, P.; Lebleu, B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 1997, 272, 16010–16017.
21. Huang, Y.; Park, Y.S.; Moon, C.; David, A.E.; Chung, H.S.; Yang, V.C. Synthetic skin-permeable proteins enabling needleless immunization. Angew. Chem. Int. Ed. Eng. 2010, 49, 2724–2727.
22. He, H.; Ye, J.; Wang, Y.; Liu, Q.; Chung, H.S.; Kwon, Y.M.; Shin, M.C.; Lee, K.; Yang, V.C. Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. J. Control. Release 2014, 176, 123–132.
23. Schwarze, S.R.; Ho, A.; Vocero-Akbani, A.; Dowdy, S.F. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 1999, 285, 1569–1572.
24. Dietz, G.P.; Bahr, M. Peptide-enhanced cellular internalization of proteins in neuroscience. Brain Res. Bull. 2005, 68, 103–114.
25. Kamei, N.; Morishita, M.; Eda, Y.; Ida, N.; Nishio, R.; Takayama, K. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J. Control. Release 2008, 132, 21–25.
26. Kamei, N.; Morishita, M.; Takayama, K. Importance of intermolecular interaction on the improvement of intestinal therapeutic peptide/protein absorption using cell-penetrating peptides. J. Control. Release 2009, 136, 179–186.
27. Barnett, E.M.; Elangovan, B.; Bullok, K.E.; Piwnica-Worms, D. Selective cell uptake of modified TAT peptide-fluorophore conjugates in rat retina in ex vivo and in vivo models. Investig. Ophthalmol. Vis. Sci. 2006, 47, 2589–2595.
28. Lopes, L.B.; Brophy, C.M.; Furnish, E.; Flynn, C.R.; Sparks, O.; Komalavilas, P.; Joshi, L.; Panitch, A.; Bentley, M.V. Comparative study of the skin penetration of protein transduction domains and a conjugated peptide. Pharm. Res. 2005, 22, 750–757.
29. Frankel, A.D.; Pabo, C.O. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988, 55, 1189–1193.
30. Green, M.; Loewenstein, P.M. Autonomous functional domains of chemically synthesized human immunodeficiency virus TAT trans-activator protein. Cell 1988, 55, 1179–1188.
31. He, H.; Ye, J.; Liu, E.; Liang, Q.; Liu, Q.; Yang, V.C. Low molecular weight protamine (LMWP): A nontoxic protamine substitute and an effective cell-penetrating peptide. J. Control. Release 2014, 193, 63–73.
32. Munyendo, W.L.; Lv, H.; Benza-Ingoula, H.; Baraza, L.D.; Zhou, J. Cell penetrating peptides in the delivery of biopharmaceuticals. Biomolecules 2012, 2, 187–202.
33. Lehto, T.; Kurrikoff, K.; Langel, U. Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin. Drug Deliv. 2012, 9, 823–836.
34. He, H.; Dong, W.; Gong, J.; Wang, J.; Yang, V.C. Developing macromolecular therapeutics: The future drug-of-choice. Front. Chem. Eng. China 2010, 4, 10–17.
35. Jarver, P.; Langel, K.; El-Andaloussi, S.; Langel, U. Applications of cell-penetrating peptides in regulation of gene expression. Biochem. Soc. Trans. 2007, 35, 770–774.
36. Chen, Y.J.; Liu, B.R.; Dai, Y.H.; Lee, C.Y.; Chan, M.H.; Chen, H.H.; Chiang, H.J.; Lee, H.J. A gene delivery system for insect cells mediated by arginine-rich cell-penetrating peptides. Gene 2011, 493, 201–210.
37. Chugh, A.; Eudes, F. Cellular uptake of cell-penetrating peptides pVEC and transportan in plants. J. Pept. Sci. 2008, 14, 477–481.
38. Dietz, G.P.; Bahr, M. Synthesis of cell-penetrating peptides and their application in neurobiology. Methods Mol. Biol. 2007, 399, 181–198.
39. Henriques, S.T.; Costa, J.; Castanho, M.A. Translocation of β-galactosidase mediated by the cell-penetrating peptide PEP-1 into lipid vesicles and human HeLa cells is driven by membrane electrostatic potential. Biochemistry 2005, 44, 10189–10198.
40. Jiang, T.; Olson, E.S.; Nguyen, Q.T.; Roy, M.; Jennings, P.A.; Tsien, R.Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc. Natl. Acad. Sci. USA 2004, 101, 17867–17872.
41. He, H.N.; Ye, J.X.; Sheng, J.Y.; Wang, J.X.; Huang, Y.Z.; Chen, G.Y. Overcoming oral insulin delivery barriers: Application of cell penetrating peptide and silica-based nanoporous composites. Front. Chem. Sci. Eng. 2013, 7, 9–19.
42. Dohmen, C.; Wagner, E. Multifunctional CPP polymer system for tumor-targeted pDNA and siRNA delivery. Methods Mol. Biol. 2011, 683, 453–463.
43. Splith, K.; Neundorf, I. Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Eur. Biophys. J. 2011, 40, 387–397.
44. Hu, J.W.; Liu, B.R.; Wu, C.Y.; Lu, S.W.; Lee, H.J. Protein transport in human cells mediated by covalently and noncovalently conjugated arginine-rich intracellular delivery peptides. Peptides 2009, 30, 1669–1678.
45. Harenberg, J.; Jeschek, M.; Acker, M.; Malsch, R.; Huhle, G.; Heene, D.L. Effects of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. Blood Coagul. Fibrinolysis 1996, 7, 49–56.
46. Wadia, J.S.; Dowdy, S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev. 2005, 57, 579–596.
47. Fonseca, S.B.; Pereira, M.P.; Kelley, S.O. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev. 2009, 61, 953–964.
48. Dietz, G.P.; Bahr, M. Delivery of bioactive molecules into the cell: The Trojan horse approach. Mol. Cell. Neurosci. 2004, 27, 85–131.
49. Chang, M.; Chou, J.C.; Chen, C.P.; Liu, B.R.; Lee, H.J. Noncovalent protein transduction in plant cells by macropinocytosis. New Phytol. 2007, 174, 46–56.
50. Hou, Y.W.; Chan, M.H.; Hsu, H.R.; Liu, B.R.; Chen, C.P.; Chen, H.H.; Lee, H.J. Transdermal delivery of proteins mediated by non-covalently associated arginine-rich intracellular delivery peptides. Exp. Dermatol. 2007, 16, 999–1006.
51. Futaki, S.; Suzuki, T.; Ohashi, W.; Yagami, T.; Tanaka, S.; Ueda, K.; Sugiura, Y. Arginine-rich peptides—An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 2001, 276, 5836–5840.
52. Ye, J.; Shin, M.C.; Liang, Q.; He, H.; Yang, V.C. 15 years of ATTEMPTS: A macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting. J. Control. Release 2015, 10, 58–69.
53. Cai, S.R.; Xu, G.; Becker-Hapak, M.; Dowdy, S.F.; McLeod, H.L. The kinetics and tissue distribution of protein transduction in mice. Eur. J. Pharm. Sci. 2006, 27, 311–319.
54. Krautwald, S.; Ziegler, E.; Rolver, L.; Linkermann, A.; Keyser, K.A.; Steen, P.; Wollert, K.C.; Korf-Klingebiel, M.; Kunzendorf, U. Effective blockage of both the extrinsic and intrinsic pathways of apoptosis in mice by TAT-crmA. J. Biol. Chem. 2010, 285, 19997–20005.
55. Essafi, M.; Baudot, A.D.; Mouska, X.; Cassuto, J.P.; Ticchioni, M.; Deckert, M. Cell-penetrating TAT-FOXO3 fusion proteins induce apoptotic cell death in leukemic cells. Mol. Cancer Ther. 2011, 10, 37–46.
56. Martin, M.E.; Rice, K.G. Peptide-guided gene delivery. AAPS J. 2007, 9, E18–E29.
57. Schwarze, S.R.; Dowdy, S.F. In vivo protein transduction: Intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharm. Sci. 2000, 21, 45–48.
58. Zanta, M.A.; Belguise-Valladier, P.; Behr, J.P. Gene delivery: A single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc. Natl. Acad. Sci. USA 1999, 96, 91–96.
59. Park, Y.J.; Liang, J.F.; Ko, K.S.; Kim, S.W.; Yang, V.C. Low molecular weight protamine as an efficient and nontoxic gene carrier: In vitro study. J. Gene Med. 2003, 5, 700–711.
60. Zatsepin, T.S.; Turner, J.J.; Oretskaya, T.S.; Gait, M.J. Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents. Curr. Pharm. Des. 2005, 11, 3639–3654.
61. Rudolph, C.; Schillinger, U.; Ortiz, A.; Tabatt, K.; Plank, C.; Muller, R.H.; Rosenecker, J. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm. Res. 2004, 21, 1662–1669.
62. Torchilin, V.P. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 2008, 90, 604–610.
63. Torchilin, V.P. TATP-mediated intracellular delivery of pharmaceutical nanocarriers. Biochem. Soc. Trans. 2007, 35, 816–820.
64. Fuente, J.M.; Berry, C.C. TAT peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug. Chem. 2005, 16, 1176–1180.
65. Walther, C.; Meyer, K.; Rennert, R.; Neundorf, I. Quantum dot-carrier peptide conjugates suitable for imaging and delivery applications. Bioconjug. Chem. 2008, 19, 2346–2356.
66. Zhang, J.; Shin, M.C.; David, A.E.; Zhou, J.; Lee, K.; He, H.; Yang, V.C. Long-circulating heparin-functionalized magnetic nanoparticles for potential application as a protein drug delivery platform. Mol. Pharm. 2013, 10, 3892–3902.
67. Zhou, J.; Zhang, J.; David, A.E.; Yang, V.C. Magnetic tumor targeting of β-glucosidase immobilized iron oxide nanoparticles. Nanotechnology 2011, 24, 375102.
68. Weisz, P.B.; Joullie, M.M.; Hunter, C.M.; Kumor, K.M.; Zhang, Z.; Levine, E.; Macarak, E.; Weiner, D.; Barnathan, E.S. A basic compositional requirement of agents having heparin-like cell-modulating activities. Biochem. Pharmacol. 1997, 54, 149–157.
69. Sheng, J.; He, H.; Han, L.; Qin, J.; Chen, S.; Ru, G.; Li, R.; Yang, P.; Wang, J.; Yang, V.C. Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates. J. Control. Release 2016, 233, 181–190.
70. Liu, E.; Sheng, J.; Ye, J.; Wang, Y.; Gong, J.; Yang, V.C.; Wang, J.; He, H. CPP mediated insulin delivery: Current status and promising future. Curr. Pharm. Biotechnol. 2014, 15, 240–255.
71. Stroh, M.; Zimmer, J.P.; Duda, D.G.; Levchenko, T.S.; Cohen, K.S.; Brown, E.B.; Scadden, D.T.; Torchilin, V.P.; Bawendi, M.G.; Fukumura, D.; et al. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat. Med. 2005, 11, 678–682.
72. Choi, Y.S.; Lee, J.Y.; Suh, J.S.; Kwon, Y.M.; Lee, S.J.; Chung, J.K.; Lee, D.S.; Yang, V.C.; Chung, C.P.; Park, Y.J. The systemic delivery of siRNAs by a cell penetrating peptide, low molecular weight protamine. Biomaterials 2010, 31, 1429–1443.
73. Herbig, M.E.; Weller, K.; Krauss, U.; Beck-Sickinger, A.G.; Merkle, H.P.; Zerbe, O. Membrane surface-associated helices promote lipid interactions and cellular uptake of human calcitonin-derived cell penetrating peptides. Biophys. J. 2005, 89, 4056–4066.
74. Zaro, J.L.; Shen, W.C. Cationic and amphipathic cell-penetrating peptides (CPPs): Their structures and studies in drug delivery. Front. Chem. Sci. Eng. 2015, 9, 407–427.
75. Wadia, J.S.; Stan, R.V.; Dowdy, S.F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 2004, 10, 310–315.
76. Duchardt, F.; Fotin-Mleczek, M.; Schwarz, H.; Fischer, R.; Brock, R. A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 2007, 8, 848–866.
77. Tunnemann, G.; Martin, R.M.; Haupt, S.; Patsch, C.; Edenhofer, F.; Cardoso, M.C. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J. 2006, 20, 1775–1784.
78. Kaplan, I.M.; Wadia, J.S.; Dowdy, S.F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control. Release 2005, 102, 247–253.
79. Wender, P.A.; Mitchell, D.J.; Pattabiraman, K.; Pelkey, E.T.; Steinman, L.; Rothbard, J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc. Natl. Acad. Sci. USA 2000, 97, 13003–13008.
80. Reissmann, S. Cell penetration: Scope and limitations by the application of cell-penetrating peptides. J. Pept. Sci. 2014, 20, 760–784.
81. Derossi, D.; Calvet, S.; Trembleau, A.; Brunissen, A.; Chassaing, G.; Prochiantz, A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J. Biol. Chem. 1996, 271, 18188–18193.
82. Richard, J.P.; Melikov, K.; Vives, E.; Ramos, C.; Verbeure, B.; Gait, M.J.; Chernomordik, L.V.; Lebleu, B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 2003, 278, 585–590.
83. Vives, E.; Richard, J.P.; Rispal, C.; Lebleu, B. TAT peptide internalization: Seeking the mechanism of entry. Curr. Protein. Pept. Sci. 2003, 4, 125–132.
84. Matsuzaki, K.; Sugishita, K.; Miyajima, K. Interactions of an antimicrobial peptide, magainin 2, with lipopolysaccharide-containing liposomes as a model for outer membranes of gram-negative bacteria. FEBS Lett. 1999, 449, 221–224.
85. Jarver, P.; Langel, U. Cell-penetrating peptides—A brief introduction. Biochim. Biophys. Acta 2006, 1758, 260–263.
86. Pan, R.; Xu, W.; Ding, Y.; Lu, S.; Chen, P. Uptake Mechanism and Direct Translocation of a New CPP for siRNA Delivery. Mol. Pharm. 2016, 13, 1366–1374.
87. Ferrari, M.E.; Nguyen, C.M.; Zelphati, O.; Tsai, Y.; Felgner, P.L. Analytical methods for the characterization of cationic lipid-nucleic acid complexes. Hum. Gene Ther. 1998, 9, 341–351.
88. Fittipaldi, A.; Ferrari, A.; Zoppe, M.; Arcangeli, C.; Pellegrini, V.; Beltram, F.; Giacca, M. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J. Biol. Chem. 2003, 278, 34141–34149.
89. Richard, J.P.; Melikov, K.; Brooks, H.; Prevot, P.; Lebleu, B.; Chernomordik, L.V. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J. Biol. Chem. 2005, 280, 15300–15306.
90. Maiolo, J.R.; Ferrer, M.; Ottinger, E.A. Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim. Biophys. Acta 2005, 1712, 161–172.
91. Lewin, M.; Carlesso, N.; Tung, C.H.; Tang, X.W.; Cory, D.; Scadden, D.T.; Weissleder, R. TAT peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 2000, 18, 410–414.
92. Grunwald, J.; Rejtar, T.; Sawant, R.; Wang, Z.; Torchilin, V.P. TAT peptide and its conjugates: Proteolytic stability. Bioconjug. Chem. 2009, 20, 1531–1537.
93. Koren, E.; Apte, A.; Sawant, R.R.; Grunwald, J.; Torchilin, V.P. Cell-penetrating TAT peptide in drug delivery systems: Proteolytic stability requirements. Drug Deliv. 2011, 18, 377–384.
94. D-amino acid cell-penetrating peptides in a cell type-dependent manner. Chem. Biol. 2011, 18, 1000–1010.
95. Sawant, R.M.; Hurley, J.P.; Salmaso, S.; Kale, A.; Tolcheva, E.; Levchenko, T.S.; Torchilin, V.P. “SMART” drug delivery systems: Double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug. Chem. 2006, 17, 943–949.
96. Omata, D.; Negishi, Y.; Hagiwara, S.; Yamamura, S.; Endo-Takahashi, Y.; Suzuki, R.; Maruyama, K.; Nomizu, M.; Aramaki, Y. Bubble liposomes and ultrasound promoted endosomal escape of TAT-PEG liposomes as gene delivery carriers. Mol. Pharm. 2011, 8, 2416–2423.
97. Kuai, R.; Yuan, W.; Li, W.; Qin, Y.; Tang, J.; Yuan, M.; Fu, L.; Ran, R.; Zhang, Z.; He, Q. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration. Mol. Pharm. 2011, 8, 2151–2161.
98. He, H.; David, A.; Chertok, B.; Cole, A.; Lee, K.; Zhang, J.; Wang, J.; Huang, Y.; Yang, V.C. Magnetic nanoparticles for tumor imaging and therapy: A so-called theranostic system. Pharm. Res. 2013, 30, 2445–2458.
99. Yu, F.; Zhang, L.; Huang, Y.; Sun, K.; David, A.E.; Yang, V.C. The magnetophoretic mobility and superparamagnetism of core-shell iron oxide nanoparticles with dual targeting and imaging functionality. Biomaterials 2010, 31, 5842–5848.
100. Stirpe, F.; Olsnes, S.; Pihl, A. Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J. Biol. Chem. 1980, 255, 6947–6953.
101. Shin, M.C.; Zhang, J.; Min, K.A.; Lee, K.; Moon, C.; Balthasar, J.P.; Yang, V.C. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy. J. Control. Release 2014, 194, 197–210.
102. Huang, Y.; Park, Y.S.; Wang, J.; Moon, C.; Kwon, Y.M.; Chung, H.S.; Park, Y.J.; Yang, V.C. ATTEMPTS system: A macromolecular prodrug strategy for cancer drug delivery. Curr. Pharm. Des. 2010, 16, 2369–2376.
103. Li, Y.T.; Kwon, Y.M.; Spangrude, G.J.; Liang, J.F.; Chung, H.S.; Park, Y.J.; Yang, V.C. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy. J. Biomed. Mater. Res. A 2009, 91, 209–220.
104. He, H.; Liang, Q.; Shin, M.C.; Lee, K.; Gong, J.; Ye, J.; Liu, Q.; Wang, J.; Yang, V. Significance and strategies in developing delivery systems for bio-macromolecular drugs. Front. Chem. Sci. Eng. 2013, 7, 496–507.
105. Lee, E.S.; Gao, Z.; Kim, D.; Park, K.; Kwon, I.C.; Bae, Y.H. Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J. Control. Release 2008, 129, 228–236.
106. Koren, E.; Apte, A.; Jani, A.; Torchilin, V.P. Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J. Control. Release 2012, 160, 264–273.
107. Quan, C.Y.; Chen, J.X.; Wang, H.Y.; Li, C.; Chang, C.; Zhang, X.Z.; Zhuo, R.X. Core-shell nanosized assemblies mediated by the alpha-beta cyclodextrin dimer with a tumor-triggered targeting property. ACS Nano 2010, 4, 4211–4219.
108. Karve, S.; Bandekar, A.; Ali, M.R.; Sofou, S. The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity. Biomaterials 2010, 31, 4409–4416.
109. Du, J.Z.; Du, X.J.; Mao, C.Q.; Wang, J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J. Am. Chem. Soc. 2011, 133, 17560–17563.
110. He, H.; Sun, L.; Ye, J.; Liu, E.; Chen, S.; Liang, Q.; Shin, M.C.; Yang, V.C. Enzyme-triggered, cell penetrating peptide-mediated delivery of anti-tumor agents. J. Control. Release 2016, 240, 67–76.
111. Zhu, L.; Kate, P.; Torchilin, V.P. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 2012, 6, 3491–3498.
112. Harris, T.J.; von Maltzahn, G.; Lord, M.E.; Park, J.H.; Agrawal, A.; Min, D.H.; Sailor, M.J.; Bhatia, S.N. Protease-triggered unveiling of bioactive nanoparticles. Small 2008, 4, 1307–1312.
113. Hatakeyama, H.; Akita, H.; Ito, E.; Hayashi, Y.; Oishi, M.; Nagasaki, Y.; Danev, R.; Nagayama, K.; Kaji, N.; Kikuchi, H.; et al. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials 2011, 32, 4306–4316.
114. Mura, S.; Nicolas, J.; Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nat. Mater. 2013, 12, 991–1003.